December 18, 2013 -- The U.S. Food and Drug Administration today approved
Anoro Ellipta (umeclidinium and vilanterol inhalation powder) for the
once-daily, long-term maintenance treatment of airflow obstruction in patients
with chronic obstructive pulmonary disease (COPD).
COPD is a serious lung disease that makes breathing difficult and worsens
over time. Symptoms can include chest tightness, chronic cough and excessive
phlegm. Cigarette smoking is the leading cause of COPD. According to the
National Heart, Lung, and Blood Institute, COPD is the third leading cause of
death in the United States
read at
http://www.drugs.com/newdrugs/fda-approves-anoro-ellipta-chronic-obstructive-pulmonary-3992.html?utm_source=ddc&utm_medium=email&utm_campaign=Today%27s+news+summary+-+December+18%2C+2013
read at
http://www.drugs.com/newdrugs/fda-approves-anoro-ellipta-chronic-obstructive-pulmonary-3992.html?utm_source=ddc&utm_medium=email&utm_campaign=Today%27s+news+summary+-+December+18%2C+2013
